PLAY PODCASTS
Pure Global: Brazil's AI MedTech Gambit - Navigating ANVISA's New Fast-Track & Privacy Traps.

Pure Global: Brazil's AI MedTech Gambit - Navigating ANVISA's New Fast-Track & Privacy Traps.

LATAM MedTech Insights · Ran Chen

March 24, 20261m 56s

Audio is streamed directly from the publisher (episodes.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This week, we dive into a major regulatory shift in Brazil. ANVISA has just launched an exciting fast-track approval process for AI-powered medical software, creating a huge opportunity for MedTech innovators to enter Latin America's biggest market faster than ever before. But this new speed comes with a hidden challenge. The new pathway is tied to incredibly strict data privacy and cybersecurity rules based on Brazil's LGPD. These new requirements around data storage and patient consent are already creating significant hurdles, turning a golden opportunity into a complex compliance trap for unprepared companies. We explore a real-world case of a US MedTech company whose Brazilian launch was stopped in its tracks by these new data privacy rules, forcing them into a difficult and expensive decision. Their cutting-edge diagnostic tool is ready, but their data is not. Key Takeaways This Episode: 1. What are the specific criteria for ANVISA's new AI software fast-track pathway? 2. How do Brazil's new data privacy mandates specifically impact MedTech device submissions? 3. Will your existing international clinical data be considered valid under the new patient consent rules? 4. What are the real costs and penalties for non-compliance with Brazil's data localization requirements? 5. Does the new regulation give local Brazilian MedTech companies an unfair advantage? 6. How can you redesign your regulatory strategy to seize the fast-track opportunity while avoiding the privacy trap? 7. What specific cybersecurity vulnerabilities is ANVISA now targeting in its assessments? Struggling to keep up with the dynamic regulatory landscape in Latin America? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local, on-the-ground expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don’t let complex regulations be a barrier to entry. Contact us at [email protected] or visit us at https://pureglobal.com/ to learn how we can accelerate your path to market.